MYOPIA AND PRESBYOPIA TREATMENT MARKET ANALYSIS

Market News

Global Myopia and Presbyopia Market: Key Developments

On October 25, 2022, Johnson & Johnson Vision, a eye health company, announced it has received approval for ACUVUE Abiliti overnight therapeutic lenses for myopia management from Health Canada, a government of Canada. These orthokeratology (ortho-k) lenses are worn overnight to reduce myopia and are uniquely created to match each patient's eye based on that eye's particular corneal shape and prescription to momentarily reshape the cornea.

On July 7, 2020, The innovative presbyopia-correcting Implantable Collamer lens ("ICL") developed by STAAR Surgical Company, a developer, manufacturer, and marketer of implantable lenses and companion delivery systems for the eye, received marketing approval for EVO Viva. The presbyopic indication for STAAR's EVO+ Visian ICL with Aspheric (EDOF) Optic, which is sold under the name "EVO Viva," received CE Mark approval from its European Notified Body, DEKRA, on July 2, 2020. Patients will initially have access to EVO Viva through a limited number of eye doctors in Spain, Germany, and Belgium.

On September 28, 2020, Johnson & Johnson Vision announced the launch of new innovative eye care solutions. The company will discuss additional clinical outcomes and field-advancing studies in addition to the first post-marketing clinical research findings on TECNIS Synergy and the TECNIS Toric II platform. The CATALYS System cOS 6.0 software, that management streamlines workflow, speeds up the surgical process and improves accuracy that offers new features for astigmatism management workflow for surgeons using the CATALYSTM Precision Laser System.